<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-02-10" updated="2019-12-02">
  <drugbank-id primary="true">DB11366</drugbank-id>
  <name>Roquinimex</name>
  <description>Roquinimex is a derivative of quinoline that presents immunostimulant properties. Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.</description>
  <cas-number>84088-42-6</cas-number>
  <unii>372T2944C0</unii>
  <average-mass>308.337</average-mass>
  <monoisotopic-mass>308.116092383</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>E. Eriksoo et al., EP 59698; eidem, U.S. Patent 4,738,971 (1982, 1988 both to AB Leo).</synthesis-reference>
  <indication>Roquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions. &#13;
&#13;
As well, roquinimex is researched to be used as adjuvant therapy after bone marrow transplantation in cases of acute leukemia. </indication>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.</description>
    <direct-parent>Aromatic anilides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Anilides</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydroquinolines</alternative-parent>
    <alternative-parent>Hydroquinolones</alternative-parent>
    <alternative-parent>Hydroxypyridines</alternative-parent>
    <alternative-parent>Hydroxyquinolines</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Pyridinecarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Pyridinones</alternative-parent>
    <alternative-parent>Quinoline-3-carboxamides</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Vinylogous acids</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>Aromatic anilide</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Dihydroquinoline</substituent>
    <substituent>Dihydroquinolone</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydroxypyridine</substituent>
    <substituent>Hydroxyquinoline</substituent>
    <substituent>Lactam</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Pyridine carboxylic acid or derivatives</substituent>
    <substituent>Pyridinone</substituent>
    <substituent>Quinoline</substituent>
    <substituent>Quinoline-3-carboxamide</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Vinylogous acid</substituent>
    <substituent>Vinylogous amide</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Linomide</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Angiogenesis Inhibitors</category>
      <mesh-id>D020533</mesh-id>
    </category>
    <category>
      <category>Angiogenesis Modulating Agents</category>
      <mesh-id>D043924</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Growth Inhibitors</category>
      <mesh-id>D006131</mesh-id>
    </category>
    <category>
      <category>Growth Substances</category>
      <mesh-id>D006133</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Quinolines</category>
      <mesh-id>D011804</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes>
    <atc-code code="L03AX02">
      <level code="L03AX">Other immunostimulants</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Roquinimex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Roquinimex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Roquinimex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Roquinimex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Pamidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Zoledronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Ibandronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Clodronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Risedronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Etidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Tiludronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06255</drugbank-id>
      <name>Incadronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Incadronic acid.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.57</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.23e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>linomide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>308.337</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>308.116092383</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C18H16N2O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>SGOOQMRIPALTEL-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>60.85</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>87.75</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>31.61</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>6.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>92056</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>54676478</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827974</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>10619239</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Roquinimex</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL11672</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11366</drugbank-id>
        <name>Roquinimex</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01690</drugbank-id>
        <name>4,8-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11366</drugbank-id>
        <name>Roquinimex</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01691</drugbank-id>
        <name>4,7-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11366</drugbank-id>
        <name>Roquinimex</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01692</drugbank-id>
        <name>4,6-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11366</drugbank-id>
        <name>Roquinimex</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01693</drugbank-id>
        <name>4-hydroxy-N-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11366</drugbank-id>
        <name>Roquinimex</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01694</drugbank-id>
        <name>4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11366</drugbank-id>
        <name>Roquinimex</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01695</drugbank-id>
        <name>4-hydroxy-N-(4-hydroxyphenyl)-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>